








Olivia Price¹, Samantha Colledge-Frisby², WILE A[[³, Rachel Sutherland¹, Paul Dietze^{2,3}, Raimondo Bruno^{1,4}, Louisa Degenhardt¹, Amy Peacock^{1,4}



lifetime incarceration, drug injected most frequently, and duration of injecting drug use.



Overall, syringe coverage has remained high over time with most participants reporting sufficient sterile coverage in both years. Coverage was high among all subpopulations examined.

Take-home naloxone coverage doubled between 2018 and 2023. This increase was observed among all subpopulations examined.

Half the 2023 sample had sufficient coverage for all relevant harm reduction interventions.